1. Metabolism, Biochemical Actions, and Chemical Synthesis of Anticancer Nucleosides, Nucleotides, and Base Analogs
   Jadd Shelton et al, 2016, Chem. Rev. CrossRef
2. null
   Aneta L. Zygulska, 2019 CrossRef
3. Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, FTD/TPI, with Ramucirumab Murine Version DC101 in a Mouse Syngeneic Cancer Transplantation Model
   Kenta Tsunekuni et al, 2020, JCM CrossRef
4. Early Clinical Experience with Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: The ROS Study
   Pilar García-Alfonso et al, 2021, Cancers CrossRef
5. Two Cases of Long-Term Control of Metastatic Colorectal Cancer via FTD/TPI plus Bevacizumab in Elderly Patients
   Masatsune Shibutani et al, 2018, Case Rep Oncol CrossRef
6. Biomarkers of Trifluridine-Tipiracil Efficacy
   Ioannis A. Voutsadakis, 2021, JCM CrossRef
7. TAS-102 Monotherapy and Combination Therapy with Bevacizumab for Metastatic Colorectal Cancer
   Cheng-Jiang Liu et al, 2021, Gastroenterology Research and Practice CrossRef
8. Targeting thymidine phosphorylase alleviates resistance to dendritic cell immunotherapy in colorectal cancer and promotes antitumor immunity
   Ankush Paladhi et al, 2022, Front. Immunol. CrossRef
9. Redefining Later-Line Therapy in Metastatic Colorectal Cancer
   Karen Yee, 2017, EMJ CrossRef
10. Anticancer effects of PEP06 (TB01) in combination with Trifluridine/Tipiracil (TAS-102) in a xenograft model of human colorectal cancer
    Ruohong Lin et al, 2024, J Cancer Res Clin Oncol CrossRef